WRLD A.LIVE

23:006 reports

• Lilly's Retatrutide Trounces Ozempic In Head-To-Head Study Investor's Business Daily
• Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial Eli Lilly
• Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study STAT
• Retatrutide Leads Obesity Pipeline Recall Amid Limited Physician Awareness of Other Treatment News, Spherix Global Insights Finds The Manila Times
• Eli Lilly Trial Shows Drug Retatrutide Produces Significant Weight Loss: Understanding the Medicine and Its Implications BusinessWorld Online
• Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial Reuters

22:00nothing heard

21:003 reports

• Steve Jobs’ son says the GLP-1 revolution could help fight cancer Fortune
• New Poll Finds Employer Benefits Support Weight Loss, But Few Address Keeping It Off Business Wire
• Employers swap GLP-1 coverage for self-pay, coaching and HSA options Benefits and Pensions Monitor

20:001 report

• Employer weight programs often end where the hard part begins Insurance Business

19:00nothing heard

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:001 report

• Hair Loss Associated With GLP-1 RAs Appear Similar by Race Medscape

13:00nothing heard

12:00nothing heard

11:001 report

• Do GLP-1 drugs pay for themselves? What five years of data show https://www.celinegounder.com/

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:001 report

• why a weight-loss drug could become a geopolitical bargaining chip BusinessWorld Online

06:00nothing heard

05:00nothing heard

04:00nothing heard

03:00nothing heard

02:001 report

• GLP-1 drug coverage is being dropped by employer plans: What to know about 2027 weight-loss options CNBC

01:001 report

• Most Patients Know About GLP-1 Uses, but Knowledge Gaps Remain Medscape